Live-attenuated chimeric vaccines
This page catalogs 2 dengue vaccine products. Dengue vaccines use chimeric live-attenuated technology and have complex eligibility requirements due to the risk of antibody-dependent enhancement (ADE) in seronegative individuals — a safety consideration that shaped both products' regulatory pathways.
Last updated: April 2026.
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Dengvaxia | CYD-TDV live-attenuated tetravalent dengue | Sanofi Pasteur | Live-attenuated chimeric viral | FDA Licensed, 2019 | Only for seropositive individuals ≥9y |
| Qdenga | TAK-003 live-attenuated tetravalent dengue | Takeda | Live-attenuated chimeric viral | EMA Authorized, 2022 | EU/Indonesia approval 2022-23 |
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026) and EMA Medicines database. Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.